Top 10 pharmaceutical companies of Brazil
Brazil today stands as the sixth largest
pharmaceutical market in the world, and recent forecasts suggest that it will
likely reach the fifth position in the coming years.
The top 10 pharmaceutical companies of Brazil are
mentioned below are:
1. Hypera Pharma
2. Roche
3. EMS
4. Novartis
5. Sanofi- Aventis
6. Eurofarma
7. Ache
8. Laboratorio Cristalia
9. Zoetis
10. Biosintetica
According to 2018 statistics
report Brazilian pharmaceutical company Hypera Pharma had the highest
net revenue, amounting to 1.15 billion U.S. dollars.
The strength of the company in the
pharmaceutical market is supported by a large-scale, low-cost operation,
centralized in the largest pharmaceutical operating complex in Latin America.
Hypera Pharma is Brazil’s largest
pharmaceutical company and operated into three major business units which are
Branded Prescriptions, Consumer Health and Generic Prescriptions.
Branded Prescriptions operates in
Primary care segments and Dermacosmetics. Branded Generics works under Neo
Quimica brand which reaches more than 80% of households in Brazil
Roche stands second over 1.06 billion dollars
net revenue in the year 2018. Founded in 1931, Roche's pharmaceutical division
in Brazil is the sixth largest affiliate of the Group in the world with 1200
employees.
Roche Group operates majorly in two divisions:
Pharmaceutical and Diagnostic. A world leader and pioneer in Hematology and
oncology. Roche Diabetes Care, is the industry leader in Brazil and worldwide,
offering practical, portable and patient-friendly systems, Accu-Chek. According
to Roche Diabetes Care Vision, by 2025, it will help people with diabetes
anywhere in the world to worry less about their daily routine so they can feel
truly free, more comfortable and flexible, all day long.
EMS stands third over 1.009 billion dollars net
revenue in the year 2018. Founded 50 years ago, EMS has been the leading
pharmaceutical industry in Brazil for over a decade. With exports to Latin
America, Europe, Africa, Asia and the Middle East, EMS is present in over 40
countries.
Cyclosporine Microemulsion, an immunosuppressant
used to combat organ rejection, is one of the main exported drugs. One of the
largest sales forces with about 1500 medical professionals and 5000 employees
throughout Brazil. EMS operates in the areas of Prescription, generic, Branded,
OTC and hospital medicines and has the largest portfolio in Brazil among
anti-inflammatory, analgesic, antibiotic, antiulcer, antihypertensive,
anthelmintic, anti-diabetic, topical and anti-influenza corticosteroids. EMS
has been the only manufacturer of the generic product in all of Latin America
for over 16 years.
Novartis stands third over 0.91 billion dollars net
revenues in 2018. For over 80 years in Brazil, Novartis has 2,700 employees and
focuses on innovation. Over the past three years, it has benefited over
30,000 patients in over 300 research centers in Brazil. Novartis Group has two
manufacturing units in Brazil that operates in the production of pharmaceutical
products for the treatment of glaucoma and post-surgery. Novartis’ Sandoz
division is a global leader in the generic and biosimilar industry.
Novartis was elected among the Most Admired
Companies in Brazil since 1997.
Another major player is Sanofi Aventis with 0.86
billion dollars net revenue in the year 2018. Over-the-counter medications
and consumer products are one of Sanofi's main lines of activity in
Brazil. It has a diverse portfolio for
treatments in therapeutic areas such as inflammation, diabetes, cardiovascular
disease and diabetes and chronic diseases.
In Brazil, Sanofi carries out collaborative
projects with universities, clinical research support and public-private
partnerships for the development of drugs, therapies and vaccines relevant to
the population.
Eurofarma stands 5th with 0.78 billion dollars net
revenue in the year 2018. Products
originating in partnerships and licenses currently account for about 3% of the
company’s total revenue. Front runners in the Prescription Drugs, Generic
Drugs, Hospital, Oncology, Nonprescription Drugs and Veterinary Medicine
segments, central nervous system (CNS), anti-infective and hormonal drugs.
Eurofarma was the only company in Brazil to launch
first generic oncological product in the early 2000s. In the year 2018 it
provided the market with the first biosimilar drug in Latin America – Fiprima®
(filgrastim), a drug used to induce an increase in the body’s defense cells for
patients with some types of cancer. The company stands tall with many awards
and certifications.
Ache contributes to 0.69 billion dollars net
revenue in 2018. With 4,700 employees and always attentive to the issue of
diversity, 52% of its employees are women. The company has a broad and
diversified portfolio, consisting of 358 brands and 145 therapeutic classes, in
the prescription, generic, over-the-counter (OTC), dermocosmetics,
dermatological drugs, nutraceuticals, probiotics and biotechnology.
The biggest patient support program, Cuidados Pela
Vida (CPV) organized by Ache, which provides patients an access to different
medicines, treatment adherence through discounts. The program also offers
services such as health reminders sent via SMS text, 24/7 Nursing Center, for clarifying doubts, web shopping,
delivering medicines at home and periodically updating health and well-being.
Another major player in the Brazil’s pharmaceutical
market is Laboratório Cristália. Founded in 2002, Latinofarma was acquired
by Cristália in 2015.
The only one in Brazil capable of developing the
entire drug chain, from the molecule conception to the final product.
Laboratorio Cristalia has 2,500 workers in Brazil, distributed in 5 main units
in the city of Sao Paulo.
The only company in Brazil which deals with animal
health products. It also conducts various learning programs for the
veterinarians. It specializes in antibiotic drugs for the animals.
Biosintética, Ache’s generic drug brand is among the first brands to obtain
generic registrations in Brazil. It generated 0.26 billion dollars net revenues
for the year 2018.
